

Authorship Responsibility and Copyright Transfer Agreement



Each author must read and agree to the statements in sections 1. (Authorship Responsibility, Criteria, and Contributions) and 3. (either Copyright Transfer or For U.S. Government Employee Authors).

Journal	<i>Hypertension</i>	Manuscript #	HYPE201914071D-AR1
Date	10-Oct-2019 06:47 GMT	IP Address	128.214.206.23
Title	Angiotensin II Conversion to Angiotensin-(1-7) in the circulation is Prolyl Oligopeptidase-Dependent and Angiotensin Converting Enzyme 2-Independent		
Authors	Peter Serfozo, Jan Wysocki, Gvantca Gulua, Arndt Schulze, Minghao Ye, Pan Liu, Jing Jin, Michael Bader, Timo Myöhänen, Arturo García-Horsman, and Daniel Batlle		

1. Authorship Responsibility, Criteria, and Contributions.

Each author should meet all criteria below (A, B, and C) and should indicate general and specific contributions by reading the criteria and checking the appropriate lines.

A. By checking this box, I certify these **three** things:

- The manuscript represents valid work and neither it nor another one that I have written with substantially similar content has been published or is being considered for publication elsewhere, except as described in an attachment.
- If asked, I will provide or fully cooperate in obtaining and providing the data on which the manuscript is based so the editors or their assignees can examine it.
- For papers with more than 1 author, I agree to allow the corresponding author to
 - be the main correspondent with the editorial office,
 - review the edited manuscript and proof, and
 - make decisions about releasing manuscript information to the media, federal agencies, or both.

If I am the only author, I will be the corresponding author and agree to handle these responsibilities.

B. I have given final approval of the submitted manuscript.

Yes No

C. I have, or a coauthor has, had sufficient access to the data to verify the manuscript's scientific integrity.

Yes No

D. I have participated sufficiently in the manuscript to take public responsibility for

part of the content **OR** the whole content.

E. To qualify for authorship, you must have made substantial contributions to the intellectual content of the paper. Please indicate your contribution(s) to this manuscript. Check all that apply:

- conceived and designed the research
- acquired the data
- analyzed and interpreted the data
- performed statistical analysis
- handled funding and supervision
- drafted the manuscript
- made critical revision of the manuscript for important intellectual content
- other

Other (please list):

2. Acknowledgment Section (for Corresponding Author Only)

Authors should obtain written permission from all individuals who are listed in the Acknowledgments section of the manuscript, because readers may infer their endorsement of data and conclusions. The corresponding author must complete this form, certifying that (1) all persons who have made substantial contributions in the manuscript (eg, data collection, analysis, or writing or editing assistance), but who do not fulfill authorship criteria, are named with their specific contributions in the Acknowledgments section of the manuscript; (2) all persons named in the Acknowledgments section have provided the corresponding author with written permission to be named in the manuscript; and (3) if an Acknowledgments section is not included, no other persons have made substantial contributions to this manuscript.

The corresponding author must check below, which serves as certification of the statements in the Acknowledgement Section.

I am the corresponding author and I certify that section 2 is true. I am a contributing author.

3. Copyright Transfer Agreement.

The American Heart Association, Inc. (AHA), a New York not-for-profit corporation, located at 7272 Greenville Avenue, Dallas, Texas 75231, and the Author hereby agree:

In consideration of the AHA reviewing and editing the Work described below for first and exclusive publication,

Journal: *Hypertension*

Manuscript #: HYPE201914071D-AR1

Authors: Peter Serfozo, Jan Wysocki, Gvantca Gulua, Arndt Schulze, Minghao Ye, Pan Liu, Jing Jin, Michael Bader, Timo Myöhänen, Arturo García-Horsman, and Daniel Batlle

Title of Work: Angiotensin II Conversion to Angiotensin-(1-7) in the circulation is Prolyl Oligopeptidase-Dependent and Angiotensin Converting Enzyme 2-Independent

The author who signs below hereby assigns, conveys, and otherwise transfers all rights, title, interest, and copyright ownership in this Work to the AHA when the AHA accepts it for publication.

- "Work" means the material submitted for publication plus any other related material submitted to the AHA.
- The rights assigned to the AHA include (but are not limited to) the rights to

- edit, publish, reproduce, distribute copies, prepare derivative works, include in indexes or search databases in print, electronic, or other media (whether or not they are used when this agreement is executed), and
- claim copyright in this Work throughout the world for as long as it is copyrighted, including renewals or extensions.

All accepted Works become the AHA's property and may not be published elsewhere without the AHA's prior written permission.

- Authors may use parts of the Work (eg, tables, figures) in subsequent works without asking the AHA's permission.

For Works created under grant and accepted for publication in an AHA journal, the author may cause the Accepted Version of the Work to be posted on the Web archive of a body that funded all or part of the Work, and/or an author's institutional repository, provided that this post appears no sooner than 6 months after the AHA publishes the Work in a journal and that the archive is publicly and noncommercially available via the World Wide Web.

- The "Accepted Version" means the paper includes peer review changes but not AHA's copyediting and production changes.
- "No sooner than 6 months after the AHA publishes the Work" means at least 6 months after the first appearance of the Work either on the AHA journal's Web site as a publish-ahead-of-print article or on the AHA journal's Web site published as part of a regular issue.

Public Access Policy Funding Disclosure:

Please disclose below if the author has received funding for research on which the article is based from any of the following organizations:

- National Institutes of Health (NIH)
- Wellcome Trust
- Howard Hughes Medical Institute (HHMI)
- Other
- None

Other (please list, using complete names and not abbreviations):

Authors hereby represent and warrant that

- they are the sole authors of the Work,
- all authors have participated in and agree with the content and Work's conclusions,
- the Work is original and does not infringe upon any copyright, proprietary, or personal right of any third party, and
- no part of it nor any Work based on substantially similar data has been submitted to another journal for publication.

If the AHA does not publish this Work, the authors will be notified and all rights given to the AHA will revert to them. If this is a joint Work, all coauthors must transfer rights in this Work to the AHA by executing this Agreement. This Agreement must be executed as is without revision or substitution of terms. This Agreement is governed by the laws of the United States.

For U.S. Government Employee Authors:

The person checking the box below hereby warrants that the Work described above was written by United States Government employees as part of their official duties and so may be published

and reproduced without restriction. (All nongovernment employee authors or coauthors must complete the prior portion of this agreement transferring copyright.)

Check this box to warrant this manuscript was written by a United States Government employee.

Author's Name: Timo Myöhänen

Date: 10-Oct-2019 06:47 GMT

IP Address: 128.214.206.23

Checking this box acts as your signature for the Authorship Responsibility and Copyright Transfer Agreement.

local_p_id: 537792

time: 1570690242

ip address: 128.214.206.23